natgillin/translations-raw huggingface dataset:
Tell your doctor about your situation BEFORE and DURING your treatment Make sure that you check the following points and tell your doctor if any of these apply to you. 
Objasnite liječniku svoje stanje PRIJE i TIJEKOM liječenja Svakako provjerite sljedeće točke i upozorite liječnika odnosi li se neka od njih na Vas.
These effects may be secondary to pup exposure to the active substance via the milk and/or maternal toxicity. 
Ti učinci mogu biti sekundarni na izloženost mladunčadi djelatnoj tvari putem mlijeka i/ili materinske toksičnosti.
Analyses of data through 96 weeks of treatment in the POWER trials demonstrated sustained antiretroviral efficacy and immunologic benefit. 
Analize podataka liječenja od 96 tjedana u ispitivanjima POWER pokazale su održanu antiretrovirusnu djelotvornost i imunološku korist.
Greater effects may be expected when fluticasone is inhaled. 
Veći učinci mogu se očekivati kada se flutikazon inhalira.
This is not a complete list of medicines. 
Ovaj popis lijekova nije potpun.
These EC50 values are well below the 50% cellular toxicity concentration range of 87 µM to > 100 µM. 
Te vrijednosti EC50 prilično su ispod 50% raspona koncentracija stanične toksičnosti od 87 μM do > 100 µM.
Virologic response was preserved throughout the study period in both arms. 
Virološki odgovor je očuvan tijekom trajanja ispitivanja u obje skupine.
Tell your doctor if you have had problems with your liver before, including hepatitis B or C infection. 
- Upozorite liječnika ako ste prije imali tegobe s jetrom, uključujući infekciju hepatitisom B ili C.
Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (frequency cannot be estimated from the available data). 
Kategorije učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
SEDATIVES/HYPNOTICS 
SEDATIVI/HIPNOTICI
Cobicistat levels decrease and may not provide sufficient boosting. 
Razine kobicistata se smanjuju i možda neće pružiti dovoljno pojačanje.
Shelf life after first opening: 3 months. 
Rok valjanosti nakon prvog otvaranja: 3 mjeseca.
Instructions for adults 
Upute za odrasle
For storage conditions after first opening of the medicinal product, see section 6.3. 
Za uvjete čuvanja nakon prvog otvaranja lijeka vidjeti dio 6.3.
Limited efficacy data are available in paediatric patients below 15 kg and no recommendation on a posology can be made. 
Dostupni su ograničeni podaci o djelotvornosti u pedijatrijskih bolesnika ispod 15 kg i nije moguće dati preporuke za doziranje.
Instructions for children 
Upute za djecu
The most frequent adverse reactions reported were diarrhoea (28%), nausea (23%), and rash (16%). 
Najčešće prijavljene nuspojave bile su proljev (28%), mučnina (23%) i osip (16%).
The exposure levels were lower than those with the recommended clinical dose in humans. 
Razine izloženosti su bile niže od onih s klinički preporučenom dozom za ljude.
(MATE1 inhibition) 
(MATE1 inhibicija)
Exposure in plasma, liver and brain was considerably higher than in adult rats after comparable doses in mg/kg between days 5 and 11 of age. 
Izloženost u plazmi, jetri i mozgu, bila je značajno viša nego u odraslih štakora, nakon usporedivih doza u mg/kg između 5. i 11. dana starosti.
Control n=124 
Kontrolna skupina n=124
Due to a decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the combination have not been established. 
Zbog smanjene izloženosti (AUC) darunaviru za 40%, primjerene kombinirane doze nisu ustanovljene.
Tell your doctor immediately if you notice any symptoms of infection (for example enlarged lymph nodes and fever). 
- Odmah upozorite liječnika ako uočite bilo kakve simptome infekcije (na primjer, povećane limfne čvorove i vrućicu).
Based upon the findings, the carbamazepine dose may need to be reduced by 25% to 50% in the presence of darunavir/ritonavir. 
Na temelju tih nalaza, dozu karbamazepina može biti potrebno smanjiti za 25% do 50% u prisustvu darunavira/ritonavira.
The main cause of these low exposures is a marked reduction in cobicistat exposure as a consequence of pregnancy-associated enzyme induction (see below). 
Glavni uzrok ovih niskih izloženosti je znatno smanjenje izloženosti kobicistatu što je posljedica indukcije enzima povezane s trudnoćom (vidjeti niže).
At least 3 oxidative metabolites of darunavir have been identified in humans; all showed activity that was at least 10-fold less than the activity of darunavir against wild type HIV. 
Ustanovljena su najmanje 3 oksidativna metabolita darunavira u ljudi; svi su pokazali aktivnost koja je bila najmanje 10 puta manja od aktivnosti darunavira protiv divljeg tipa HIV-a.
Some additional tests might be necessary. 
Možda će biti potrebno učiniti neke dodatne pretrage.
800 milligram 
800 miligrama
The child must swallow the tablets with a drink such as water or milk. 
- Dijete mora progutati tablete s pićem poput vode ili mlijeka.
This cannot be administered with these 600 milligram tablets. 
To se ne može primijeniti s ovim tabletama od 600 miligrama.
Swallow the tablets with a drink such as water or milk. 
- Progutajte tablete s pićem poput vode ili mlijeka.
In vitro selection of darunavir-resistant virus from wild type HIV-1 was lengthy (> 3 years). 
In vitro selekcija virusa rezistentnog na darunavir iz divljeg tipa HIV-1 bila je dugotrajna (> 3 godine).
If prescribed Darunavir Krka twice daily the child must take one dose in the morning, and one dose in the evening. 
Ako je Darunavir Krka propisan dvaput na dan dijete mora uzeti jednu dozu ujutro, a jednu dozu navečer.
The safety assessment in paediatric patients is based on the 48-week analysis of safety data from three Phase II trials. 
Procjena sigurnosti u pedijatrijskih bolesnika temelji se na 48-tjednoj analizi podataka o sigurnosti dobivenim u tri ispitivanja faze II.
Do not use this medicine after the expiry date which is stated on the packaging after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju iza oznake EXP.
The clinical relevance of the increase in norbuprenorphine pharmacokinetic parameters has not been established. 
Klinički značaj povišenja farmakokinetičkih parametara norbuprenorfina nije ustanovljen.
Glecaprevir/pibrentasvir 
Glekaprevir/pibrentasvir
Interaction Geometric mean change (%) 
Promjena geometrijske srednje vrijednosti (%)
However, only limited data were available in patients above the age of 65 year. 
Međutim, za bolesnike u dobi iznad 65 godina bili su dostupni samo ograničeni podaci.
People taking Darunavir Krka may still develop infections or other illnesses associated with HIV infection. 
Osobe koje uzimaju Darunavir Krka i dalje mogu razvijati infekcije ili druge bolesti povezane s HIV infekcijom.
There are no adequate and well controlled studies on pregnancy outcome with darunavir in pregnant women. 
Nisu provedena odgovarajuća i dobro kontrolirana ispitivanja o ishodu trudnoće s darunavirom u trudnica.
In juvenile rats receiving darunavir up to days 23-26, increased mortality was observed with convulsions in some animals. 
U mladih štakora koji su primali darunavir do 23-26 dana života, primijećen je povećani mortalitet s konvulzijama u nekih životinja.
Darunavir Krka with food and drink See section 3 ‘How to take Darunavir Krka.' 
Darunavir Krka s hranom i pićem Vidjeti dio 3 „Kako uzimati Darunavir Krka.“
In the table below the specific pharmacokinetic enhancer is specified when recommendations differ. 
U tablici ispod, određeni farmakokinetički pojačivač naveden je posebno, ako se preporuke razlikuju.
Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients. 
Moraju se uzeti u obzir službene smjernice primjerenog liječenja tuberkuloze u HIV-om inficiranih bolesnika.
Your doctor will discuss with you which combination of medicines is best for you. 
Liječnik će Vam objasniti koja je kombinacija lijekova najbolja za Vas.
The total mean treatment duration for subjects was 95.3 weeks. 
Ukupna srednja vrijednost trajanja liječenja ispitanika bila je 95,3 tjedna.
Your doctor may evaluate how severe your liver disease is before deciding if you can take Darunavir Krka. 
Liječnik može procijeniti koliko je teška Vaša bolest jetre prije nego što odluči možete li uzimati lijek Darunavir Krka.
Daily doses of 150, 450 and 1,000 mg/kg were administered to mice and doses of 50, 150 and 500 mg/kg were administered to rats. 
Dnevne doze od 150, 450 i 1000 mg/kg bile su primijenjene miševima te doze od 50, 150 i 500 mg/kg bile su primijenjene štakorima.
Dose-related increases in the incidences of hepatocellular adenomas and carcinomas were observed in males and females of both species. 
S dozom povezana povišenja incidencije hepatocelularnog adenoma i karcinoma bilo je opaženo u mužjaka i ženki obje vrste.
This was driven by mild intensity nausea. 
Radilo se o mučnini blagog intenziteta.
This product is only available as film coated tablets and is thus not suitable for patients who are unable to swallow intact tablets, for example young children. 
Ovaj je lijek dostupan samo u obliku filmom obloženih tableta i stoga nije prikladan za bolesnike koji ne mogu progutati čitave tablete, na primjer mala djeca.
Out of the 59 patients who responded with complete viral suppression (< 50 copies/ml) at week 48, 47 patients (80% of the responders at week 48) remained responders at week 96. 
Od 59 bolesnika koji su odgovorili potpunom virusnom supresijom (< 50 kopija/ml) u 48. tjednu, 47 bolesnika (80% odgovora u 48. tjednu) pokazalo je odgovor i u 96. tjednu.
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Germany 
TAD Pharma GmbH Heinz-Lohmann-Straβe 5 27472 Cuxhaven Njemačka
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. 
Prema postojećim smjernicama liječenja općenito se ne preporučuje dvojna terapija inhibitorima proteaze.
Total number of virologic failures a, n (%) 
Ukupan broj viroloških neuspjeha a, n (%)
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products. 
U slučaju istodobne antivirusne terapije za hepatitis B ili C, potrebno je slijediti relevantne Upute o lijeku koji postoje za te lijekove.
The type of food does not affect exposure to darunavir. 
Vrsta hrane ne utječe na izloženost darunaviru.
If you belong to this age group, please discuss with your doctor if you can use Darunavir Krka. 
Ako pripadate toj dobnoj skupini, molimo Vas da s liječnikom razmotrite smijete li uzimati lijek Darunavir Krka.
Studies in rats have demonstrated that darunavir is excreted in milk and at high levels (1,000 mg/kg/day) resulted in toxicity. 
Ispitivanja na štakorima pokazala su da se darunavir izlučuje u mlijeku i na visokim razinama (1000 mg/kg/dan) dovodi do toksičnosti.
In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued. 
U više od polovice prijavljenih slučajeva, liječenje inhibitorima proteaze je nastavljeno ili je ponovno uvedeno u slučaju prekida liječenja.
Tell your doctor if you are allergic to sulphonamides (e.g. used to treat certain infections). 
- Upozorite liječnika ako ste alergični na sulfonamide (upotrebljavaju se npr. za liječenje nekih infekcija).
In case of safety issues, a further increase of the dosing interval for rifabutin and/or monitoring of rifabutin levels should be considered. 
U slučaju sigurnosnih problema, mora se razmotriti daljnje povećanje intervala doziranja rifabutina i/ili praćenje razina rifabutina.
What Darunavir Krka is and what it is used for 
Što je Darunavir Krka i za što se koristi
These are mentioned above under the heading ‘Do not combine Darunavir Krka with any of the following medicines:' 
Navedeni su gore pod naslovom „Nemojte kombinirati Darunavir Krka ni s jednim od sljedećih lijekova“.
However, unbound darunavir concentrations were approximately 55% (Child-Pugh Class A) and 100% (ChildPugh Class B) higher, respectively. 
Unatoč tome, koncentracije nevezanog darunavira bile su približno 55% (Child-Pugh stadij A) i 100% (Child-Pugh stadij B) više.
15 kg to < 20 kg N=16 
15 kg do < 20 kg N=16
100 milligram between 30 and 40 kilograms 675 milligram 
100 miligrama između 30 i 40 kilograma 675 miligrama
Treatment of overdose with darunavir consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. 
Liječenje predoziranja darunavirom sastoji se od općenitih potpornih mjera koje uključuju praćenje vitalnih znakova i promatranje kliničkog statusa bolesnika.
β-BLOCKERS Carvedilol Metoprolol Timolol 
β-BLOKATORI Karvedilol Metoprolol Timolol
Data based on analyses at week 48 
Podaci temeljeni na analizama u 48. tjednu
A variable but limited decrease in red blood cell-related parameters was observed, together with increases in activated partial thromboplastin time. 
Primijećeno je varijabilno, ali ograničeno smanjenje parametara koji se odnose na eritrocite, zajedno s povećanjima aktiviranog parcijalnog tromboplastinskog vremena.
A causal relationship has been suggested, although the mechanism of action has not been elucidated. 
Pretpostavlja se da postoji uzročno posljedična povezanost, iako mehanizam djelovanja nije razjašnjen.
Dose adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered. 
Mora se uzeti u obzir prilagodba doze midazolama, posebno u slučaju primjene više od jednokratne doze midazolama.
Psychiatric disorders common abnormal dreams 
Psihijatrijski poremećaji često nenormalni snovi
ART-experienced patients - once daily dosing 
ART-om prethodno liječeni bolesnici - doziranje jedanput na dan
Please contact your doctor whenever you develop a rash. 
Molimo obratite se svom liječniku kad god dobijete osip.
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations. 
Povišenje doze ritonavira od one preporučene u dijelu 4.2 nije imalo značajan učinak na koncentracije darunavira.
CCR5 ANTAGONIST Maraviroc 
ANTAGONIST CCR5 Maravirok
Darunavir is approximately 95% bound to plasma protein. 
Darunavir se približno 95% veže na proteine plazme.
Treatment difference 
Razlika liječenja
The child must take the appropriate doses of Darunavir Krka and ritonavir two times per day or once a day. 
- Dijete mora uzimati odgovarajuće doze lijeka Darunavir Krka i ritonavira dvaput na dan ili jedanput na dan.
The risk of muscle damage might be increased. 
Može biti povećan rizik oštećenja mišićnog tkiva.
POWER 1 and POWER 2 pooled data Week 48 
Objedinjeni podaci ispitivanja POWER 1 i POWER 2 48. tjedan
The substantial reduction in darunavir exposure may result in virological failure and an increased risk of mother to child transmission of HIV infection. 
Znatno smanjenje izloženosti darunaviru može rezultirati virološkim neuspjehom i povećnim rizikom za prijenos HIV infekcije s majke na dijete.
This strength is not suitable for dosages below 600 mg. 
Ova jačina nije prikladna za doziranje ispod 600 mg.
ODIN Week 48 
ODIN 48. tjedan
One dose is between 15 and 30 kilograms 
Jedna doza je između 15 i 30 kilograma
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. 
Duljina kombinirane antiretrovirusne terapije, korištenje kortikosteroida, konzumiranje alkohola, teška imunosupresija, viši indeks tjelesne mase, između ostaloga, mogu biti neki od mnogih faktora rizika za razvoj ove bolesti.
Dose(twice daily with food) 
Doza (dvaput na dan s hranom)
The rash is usually mild to moderate. 
Osip je obično blag do umjeren.
In a study conducted in rats, the number of corpora lutea and implantations were decreased in the presence of maternal toxicity. 
U provedenom istraživanju na štakorima, broj žutih tijela i implantacija bio je smanjen uz prisustvo maternalne toksičnosti.
Studies in animals do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Ispitivanja na životinjama ne pokazuju izravne štetne učinke s obzirom na trudnoću, embrio/fetalni razvoj, porod ili postnatalni razvoj (vidjeti dio
(P-gp, BCRP and/or OATP1B1/3 inhibition) 
(P-gp, BCRP i/ili OATP1B1/3 inhibicija)
100 milligram more than 40 kilograms 
100 miligrama više od 40 kilograma
* Using cross-study comparisons to historical pharmacokinetic data 
* Koristeći unakrižnu usporedbu ispitivanja s prethodnim farmakokinetičkim podacima
A lower dose of the β-blocker should be considered. 
Mora se uzeti u obzir niža doza β-blokatora.
Caution is warranted and clinical monitoring is recommended. 
Potreban je oprez i preporučuje se kliničko praćenje.
According to the TLOVR non-virologic failure censored algorithm 24 (30.0%) patients experienced virological failure, of which 17 (21.3%) patients were rebounders and 7 (8.8%) patients were nonresponders. 
Prema TLOVR cenzoriranom algoritmu nevirološkog neuspjeha 24 (30,0%) bolesnika je doživjelo virološki neuspjeh, od čega je 17 (21,3%) bolesnika bilo s povratnim virološkim neuspjehom i 7 (8,8%) bolesnika je bilo bez odgovora.
Nervous system disorders very common headache 
Poremećaji živčanog sustava vrlo često glavobolja
The increased exposure was likely at least partly due to immaturity of the drug-metabolising enzymes in juvenile animals. 
Izloženost je vjerojatno povećana barem djelomično i zbog nerazvijenih enzima koji metaboliziraju lijek u mladih životinja.
Tablets of lower strengths are available to construct the appropriate dosing regimen. 
Dostupne su i tablete manjih jačina kojima se može dosegnuti odgovarajući režim doziranja lijeka.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS NS3-4A protease inhibitors 
ANTIVIRUSNI LIJEKOVI DIREKTNOG DJELOVANJA NA VIRUS HEPATITISA C (HCV) NS3-4A inhibitori proteaze
Administration of darunavir did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats. 
Primjena darunavira nije uzrokovala statistički značajno povišenje incidencije bilo koje druge benigne ili maligne neoplazme u miševa i štakora.
Population pharmacokinetic analysis showed a slightly higher darunavir exposure (16.8%) in HIV infected females compared to males. 
Analiza populacijskih farmakokinetičkih podataka pokazala je neznatno višu izloženost darunaviru (16,8%) u HIV-om inficiranih žena u usporedbi s muškarcima.
There are some medicines that you must not combine with Darunavir Krka. 
Postoje neki lijekovi koje ne smijete kombinirati s lijekom Darunavir Krka.
Dasatinib Nilotinib Vinblastine Vincristine 
Dasatinib Nilotinib Vinblastin Vinkristin
This will improve your immune system and reduces the risk of developing illnesses linked to HIV infection. 
Vaš imunološki sustav i smanjiti rizik od razvoja bolesti koje su vezane za HIV infekciju.
Your doctor will evaluate which cholesterol lowering regimen is best for your specific situation. 
Liječnik će procijeniti koji način liječenja povišenog kolesterola najbolje odgovara Vašoj specifičnoj situaciji.
Dose (once daily with food) 
Doza (jedanput na dan s hranom)
b fold change in EC50 “Patients with no/non-naïve use of ENF” are patients who did not use ENF or who used ENF but not for the first time “Patients with naïve use of ENF” are patients who used ENF for the first time 
b promjena vrijednosti EC50 “Bolesnici koji još nisu uzimali/ne uzimaju prvi put ENF” uključuje bolesnike koji još nisu uzimali ENF ili su ga uzimali, ali ne prvi put “ Bolesnici bez iskustva u liječenju s ENF” uključuje bolesnike koji su u ispitivanju ENF uzeli prvi put
It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles. 
On selektivno inhibira cijepanje HIV-om kodiranih Gag-Pol poliproteina u stanicama inficiranim virusom, sprečavajući na taj način formiranje zrelih infektivnih virusnih čestica.
R(-) methadone AUC ↓ 16% R(-) methadone Cmin ↓ 15% R(-) methadone Cmax ↓ 24% 
R(-) metadon AUC ↓ 16% R(-) metadon Cmin ↓ 15% R(-) metadon Cmax ↓ 24%
Rifabutin 150 mg once every other day rifabutin AUC rifabutin Cmin 
Rifabutin 150 mg jedanput svaki drugi dan rifabutin AUC rifabutin Cmin
UNIQUE IDENTIFIER - HUMAN READABLE DATA 
JEDINSTVENI IDENTIFIKATOR - PODACI ČITLJIVI LJUDSKIM
When co-administration is required the daily dose of itraconazole should not exceed 200 mg. 
Kada se zahtijeva istodobna primjena, dnevna doza itrakonazola ne smije prelaziti 200 mg.
The digoxin dose should be carefully titrated to obtain the desired clinical effect while assessing the overall clinical state of the subject. 
Doza digoksina mora se pažljivo titrirati kako bi se postigao željeni klinički učinak dok se procjenjuje ukupno kliničko stanje bolesnika.
Very common side effects (may affect more than 1 in 10 people) diarrhoea. 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba)
In the virologic failures of the GS-US-216-130 trial no cross-resistance with other HIV PIs was observed. 
Kod viroloških neuspjeha u ispitivanju GS-US-216-130 nije uočena križna rezistencija s drugim HIV IP.
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account. 
Općenito pravilo je da se, pri donošenju odluke o primjeni antiretrovirusnih lijekova za liječenje HIV infekcije u trudnica i posljedično smanjenje rizika od vertikalnog prijenosa HIV-a na novorođenče, u obzir uzmu podaci dobiveni na životinjama kao i kliničko iskustvo u trudnica.
The dose of other pharmacokinetic enhancer to be used with darunavir in children less than 18 years of age has not been established. 
Doza drugih farmkokinetičkih pojačivača koja se treba uzeti uz darunavir u djece dobi mlađe od 18 godina nije ustanovljena.
Please discuss with your doctor which dose is right for you. 
Molimo razgovarajte sa svojim liječnikom o tome koja je prava doza za Vas.
The clinical relevance of this increase is unknown therefore, darunavir should be used with caution. 
Klinički značaj ovog povišenja nije poznat, stoga se darunavir mora primijenjivati s oprezom.
Lurasidone Pimozide Sertindole 
Lurasidon Pimozid Sertindol
DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens-Johnson Syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported. 
DRESS (osip izazvan lijekom s eozinofilijom i sistemskim simptomima) i Stevens-Johnsonov sindrom bili su rijetko (< 0,1%) prijavljivani, a tijekom postmarketinškog iskustva prijavljene su toksična epidermalna nekroliza i akutna generalizirana egzantematozna pustuloza.
Pharmacotherapeutic group: antivirals for systemic use, protease inhibitors, ATC code: J05AE10. 
Farmakoterapijska skupina: Antivirusni lijekovi za sistemsku primjenu, inhibitori proteaze, ATK oznaka: J05AE10.
These can be seen in the results of blood and/or urine tests. 
To se može vidjeti iz rezultata krvnih pretraga i/ili pretraga mokraće.
C-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of 
C-darunavira s ritonavirom, približno 79,5% i 13,9%
ANTIPSYCHOTICS/NEUROLEPTICS Quetiapine 
ANTIPSIHOTICI/NEUROLEPTICI Kvetiapin
Amiodarone Bepridil Dronedarone Ivabradine Quinidine Ranolazine 
Amiodaron Bepridil Dronedaron Ivabradin Kinidin Ranolazin
Unlike ritonavir, cobicistat does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. 
Za razliku od ritonavira, kobicistat ne inducira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ili UGT1A1.
6/l (see section 4.2 and 4.4). 
6/l (vidjeti dijelove 4.2 i 4.4).